
Yuji Oba

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10459860/publications.pdf Version: 2024-02-01



Υιμι Οβά

#	Article	IF	CITATIONS
1	Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis. The Cochrane Library, 2020, , .	2.8	1
2	Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis. The Cochrane Library, 2020, , .	2.8	1
3	Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. The Cochrane Library, 2018, 2018, CD012620.	2.8	52
4	Fixed-dose combination inhalers compared to long-acting bronchodilators for COPD: a network meta-analysis. The Cochrane Library, 2017, , .	2.8	1
5	Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 677-685.	1.6	11
6	Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax, 2016, 71, 15-25.	5.6	105
7	Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression. Therapeutic Advances in Respiratory Disease, 2015, 9, 3-15.	2.6	17
8	Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis. International Journal of COPD, 2014, 9, 469.	2.3	26
9	Mortality benefit of vasopressor and inotropic agents in septic shock: A Bayesian network meta-analysis of randomized controlled trials. Journal of Critical Care, 2014, 29, 706-710.	2.2	32
10	Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Therapeutic Advances in Respiratory Disease, 2013, 7, 13-24.	2.6	57
11	Phosphodiesterase Inhibitors in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 1366-1366.	5.6	1
12	Cardiovascular Safety of Roflumilast. Chest, 2013, 144, 1082.	0.8	0
13	Roflumilast: a green signal is yet to come. Journal of Thoracic Disease, 2013, 5, 213-5.	1.4	1
14	High levels of PEEP may improve survival in acute respiratory distress syndrome: A meta-analysis. Respiratory Medicine, 2009, 103, 1174-1181.	2.9	49
15	Cost-effectiveness of long-term oxygen therapy for chronic obstructive disease. American Journal of Managed Care, 2009, 15, 97-104.	1.1	13
16	Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. American Journal of Managed Care, 2009, 15, 226-32.	1.1	18
17	Safety, tolerability and risk benefit analysis of tiotropium in COPD. International Journal of COPD, 2008, Volume 3, 575-584.	2.3	27
18	Cost-Effectiveness of Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. Mayo Clinic Proceedings, 2007, 82, 575-582.	3.0	41

#	Article	IF	CITATIONS
19	Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. Journal of Allergy and Clinical Immunology, 2004, 114, 265-269.	2.9	133